Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition
The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc. and Sanofi SA partnered Dupixent (dupilumab) for treating allergic fungal rhinosinusitis (AFRS).
• Regeneron Pharmaceuticals stock is facing resistance.
AFRS is a condition characterized by allergic hypersensitivity to fungi, which often leads to chronic sinus issues and surgery.
The approval covers Dupixent for patients aged six years and older with a history of sino-nasal surgery.
The approval is based on Phase 3 trial results that demonstrated Dupixent’s effectiveness in reducing nasal symptoms and the need for systemic corticosteroids or surgery compared to placebo.
Dupixent is now approved for nine distinct diseases driven by type 2 inflammation, including chronic rhinosinusitis with nasal polyps.
Technical Analysis
Currently, the stock is trading 5.2% below its 20-day simple moving average (SMA) and 8.4% below its 100-day SMA, indicating short-term weakness. Over the past 12 months, shares have increased approximately 64%, and they are currently positioned closer to their 52-week highs than lows, reflecting a generally positive long-term trend.
The RSI is at 50.00, which is considered neutral territory, suggesting the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.10, below its signal line at 0.15, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in market sentiment.
- Key Resistance: $821
- Key Support: $750
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $819.70. Recent analyst moves include:
- Guggenheim: Buy (Raises target to $975 on Feb. 9)
- JP Morgan: Overweight (Raises target to $950 on Feb. 2)
- Oppenheimer: Outperform (Raises target to $865 on Feb. 2)
REGN Price Action: Regeneron Pharmaceuticals shares were down 0.77% at $781.01 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo: Shutterstock AI Generator
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Zoom (ZM.US) gets a bullish rating from Citi ahead of earnings: AI monetization signals emerge, target price raised to $131
Citibank has issued a forecast ahead of Zoom's Q3 financial report: Two major signals from channel partner surveys and Analyst Day both reinforce its view of a "moderate acceleration in the second half of the year."

JPMorgan: The CUDA moat is crumbling, and Nvidia faces real challenges beyond the CEO's departure
JPMorgan points out that Nvidia’s share in the 2026 compute protocol will drop to just 28%, with strong competition emerging from AMD, Google TPU, and others. Meanwhile, CUDA’s moat was breached by AI in only three days. The open-source market is facing tightened regulation and increased risks of export compliance. Although Nvidia’s current valuation remains attractive, both major drivers supporting high growth expectations have been undermined.
Bridgewater's $23 Billion Portfolio Reshuffle: Drops Google (GOOGL.US) and Amazon (AMZN.US), Increases Holdings in AI Hardware and Energy
Bridgewater's Q3 portfolio was restructured, with a total market value of $23 billion. The fund significantly increased holdings in AI hardware and energy stocks such as Qualcomm and Micron, reduced positions in Google, Amazon, and S&P 500 ETF, and fully exited industrial stocks like Union Pacific, with a notable increase in the weighting of the healthcare sector.

